MiR-532-3p suppresses cell proliferation, migration and invasion of colon adenocarcinoma via targeting FJX1.

OBJECTIVE: We attempted to probe into mechanism of FJX1 regulating cell behaviors of colon adenocarcinoma, and to provide ideas for targeted therapy of colon adenocarcinoma. METHODS: Differential mRNAs were screened out from TCGA-COAD dataset. K-M analysis was done to compare correlation between FJX1 expression and patient's survival status. Upstream miRNAs of FJX1 were identified by bioinformatics methods. Targeted relationship of miR-532-3p and FJX1 was verified by dual-luciferase reporter gene assay. FJX1 level in colon adenocarcinoma cell lines was assayed via qRT-PCR and western blot. The impact of regulation of miR-532-3p to FJX1 on biological functions of colon adenocarcinoma cells was evaluated by MTT, wound healing and Transwell invasion assays. RESULTS: TCGA-COAD data and qRT-PCR manifested that FJX1 was increased in colon adenocarcinoma tissue, while miR-532-3p was conspicuously less expressed. Survival analysis denoted that FJX1 is potential to be an independent prognosticator in colon adenocarcinoma. Dual-luciferase assay manifested that miR-532-3p targeted FJX1 to repress expression of FJX1. Overexpression of FJX1 could stimulate cell malignant behaviors of colon adenocarcinoma, whereas forced expression of miR-532-3p reversed this promotive effect. CONCLUSION: This study revealed that FJX1 was an oncogene in colon adenocarcinoma cells, which was regulated by miR-532-3p. MiR-532-3p targeted and regulated FJX1 expression to suppress cell malignant behaviors of colon adenocarcinoma.

[Sustained dynamic release characteristics of fibrin glue enwrapping cisplatin].

OBJECTIVE: To summarize the sustained dynamic release characteristics of fibrin glue enwrapping cisplatin. METHODS: In this in vivo study, 20 patients received fibrin glue enwrapping cisplatin placed into the abdominal cavity while another 20 patients received cisplatin as the control group. Their peripheral blood and urine samples were collected at a regular interval to determine the concentrations and the pharmacokinetic parameters of cisplatin. RESULTS: The peak peripheral blood concentration of cisplatin in the study group was significantly lower than that in the control group [(192.2 ± 33.5) vs (1077.6 ± 176.6) µg/L, P < 0.01]. And the peak urine concentration of cisplatin was significantly lower in the study group than that in the control group [(18.6 ± 8.7) vs (55.8 ± 12.7) µg/L, P < 0.01]. The elimination half-life of cisplatin was 23.32 h and 13.93 h respectively in the study and control groups. The elimination half-life and the area under the curve in peripheral blood and urine samples of the study group were significantly longer than those of the control group (P < 0.01). CONCLUSION: The fibrin glue enwrapping cisplatin has the excellent in vivo characteristics of sustained dynamic release. Thus it may prolong the retention of cisplatin in abdominal cavity and lower its concentration in peripheral blood.